Peptide Longevity Q&A ·
Research indicates that Tesamorelin, a stabilized analogue of human GHRH, increases GABA levels in the brains of older adults with mild cognitive impairment and those with normal cognitive function after 20 weeks of administration, suggesting potential cognitive benefits.
What the research shows
The study investigated the neurochemical effects of Tesamorelin, a growth hormone-releasing hormone (GHRH) analogue, in a randomized, double-blind, placebo-controlled trial involving thirty adults aged 55 to 87 years. Among these participants, 17 had mild cognitive impairment (MCI). Over a period of 20 weeks, participants self-administered daily subcutaneous injections of Tesamorelin (1 mg/d) or a placebo before bedtime. The research aimed to measure changes in brain levels of various neurotransmitters, specifically γ-aminobutyric acid (GABA), as well as other metabolites using proton magnetic resonance spectroscopy. Cognitive testing and blood samples were also collected at baseline and at weeks 10 and 20 of the study.
Why it matters for longevity
The increase in GABA levels observed in the study is significant because GABA is an inhibitory neurotransmitter that plays a crucial role in regulating neuronal excitability and maintaining cognitive function. Age-related cognitive decline, particularly in individuals with MCI, is a growing concern as it can lead to more severe neurodegenerative conditions. By enhancing GABA levels, Tesamorelin may contribute to improved cognitive outcomes, thereby potentially extending healthspan and quality of life in older adults. This research suggests a possible mechanism through which GHRH analogues like Tesamorelin could exert positive effects on brain health and cognitive function.
Key findings at a glance
- Twenty weeks of Tesamorelin administration increased GABA levels in all measured brain regions.
- NAAG levels were also increased in the dorsolateral frontal cortex.
- Myo-inositol levels decreased in the posterior cingulate region.
- Similar effects were noted in both adults with mild cognitive impairment and those with normal cognitive function.
- No significant changes in glutamate levels were observed.
- The study provided preliminary support for GHRH effects on cognition.
How Tesamorelin works (background)
Tesamorelin functions as a stabilized analogue of human growth hormone-releasing hormone (GHRH). GHRH stimulates the secretion of growth hormone from the pituitary gland, which in turn influences various metabolic processes and may enhance cognitive function. The modulation of neurotransmitter levels, particularly GABA, may be one mechanism through which Tesamorelin exerts its effects. GABA's role in inhibiting excessive neuronal firing is critical for maintaining cognitive stability, especially in aging populations.
Safety, caveats, and what we don't yet know
While the study indicates that Tesamorelin may increase GABA levels and potentially improve cognitive function, it is essential to note that the research is limited to a small sample size and a specific age group. The long-term safety profile of Tesamorelin in diverse populations has not been fully established. Further research is needed to understand the broader implications of GHRH analogues on cognitive health and their potential effects in various demographic groups, including those with different underlying health conditions.
Bottom line
In summary, Tesamorelin has been shown to increase GABA levels in older adults, which may have implications for cognitive health and longevity.
Related questions
Can Tesamorelin improve cognitive function in older adults?
Research suggests that Tesamorelin may enhance cognitive function through its effects on neurotransmitter levels, particularly GABA, in older adults.
What are the potential benefits of GHRH analogues for aging?
GHRH analogues like Tesamorelin may help improve cognitive function and metabolic health in aging populations by modulating neurotransmitter levels.
Are there any risks associated with Tesamorelin use?
While Tesamorelin appears to have cognitive benefits, its long-term safety and effects in various populations require further investigation.
Source: PubMed · JAMA Neurol · published 2013-07-01.